Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis

Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis have?

Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis has 3 citations in the OpenAlex counts ScholarIQ stores.

When was Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis published?

Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis has 2024 year in the ScholarIQ index.

What is the open-access status of Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis?

Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis has hybrid oa status in the ScholarIQ index.

What is the DOI of Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis?

The DOI for Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis is on the source record.

What is the PMID of Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis?

The PMID for Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis is on the source record.

What is the OpenAlex record for Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis?

The OpenAlex for Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis is on the source record.